IL-AG v. Mylan Inc.

Mylan Inc. allegedly monopolized the epinephrine auto-injector market through a variety of anticompetitive tactics, including increasing prices, delaying generic versions of EpiPen, forcing consumers to unnecessarily buy EpiPens in two-packs instead of a single pen, creating misleading advertisements concerning competing products, and contracting with third-party pharmacy benefit managers to block competitors to EpiPen. These actions appear to have resulted in the state of Illinois paying excess amounts for EpiPens purchased through its Medicaid and employee health benefits programs.

Summary generated from official Illinois Attorney General press release